drugset
drugset / Trial / NCT05923892

Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type

NCT05923892 ↗

Phase 2 Completed 87 enrolled Otsuka Beijing Research Institute
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Different Doses of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea type (IBS-D).The trial is mainly divided into three periods: screening period, treatment period and follow-up period.

Timeline

Start
2023-08-02
Primary completion
2024-08-01
Completion
2024-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject OPS-2071 Small molecule 50 mg Oral
Subject OPS-2071 Small molecule 100 mg Oral
Subject OPS-2071 Small molecule 200 mg Oral

Indications

irritable bowel syndrome